<DOC>
	<DOCNO>NCT01611077</DOCNO>
	<brief_summary>The investigator want find treatment new combination two different antihypertensive drug ( olmesartan amlodipine ) one tablet patient moderately elevate blood pressure effective treatment one substance ( candesartan ) . All antihypertensive treatment cease two week achieve comparable baseline condition . Treatment start single substance . After six week , therapy change another single substance six week , fix combination tablet . Blood pressure determine office measurement take doctor via long-term ambulatory blood pressure monitoring ( ABPM ) . Participants may male female must 18 year age .</brief_summary>
	<brief_title>Efficacy Safety Therapy Change From Candesartan 32 mg Fixed Combination Olmesartan 40 mg/Amlodipine 10 mg</brief_title>
	<detailed_description>SEVICONTROL-2 : Efficacy Safety sequential therapy change Candesartan 32 mg fix combination olmesartan 40 mg/amlodipine 10 mg patient poorly control moderate hypertension - open phase IV trial</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>male female patient &gt; = 18 year age essential hypertension , i. e. systolic office bp &gt; = 140 mmHg pretreated patient &gt; = 160 mmHg untreated patient screen visit &gt; = 160 mmHg end washout sign IC systolic office bp &gt; 180 mm Hg screen visit know hypertensive retinopathy GIII IV recent ( &lt; 4 week ago ) myocardial infarction indication coronary peripheral revascularisation type I diabetes poorly control ( HbA1c &gt; = 8 ) type II diabetes chronic heart failure NYHA III IV prior stroke TIA creatinine clearance &lt; 60 ml/min condition kidney transplant moderately severely impaired liver function ( ALT AST bilirubin double normal value ) woman childbearing potential without highly effective contraception , pregnant breastfeed woman concomitant therapy lithium hemodynamically relevant mitral aortic valve stenosis ( &gt; = IIÂ° ) hypertrophic obstructive cardiomyopathy concomitant therapy strong CYP3A4 inhibitor inductor african patient concomitant severe psychiatric condition might impair proper intake study medication life expectancy &lt; 6 month night shift worker known mandatory indication treatment antihypertensive medication parallel participation clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>